Brief: Aldeyra Therapeutics Resubmits Reproxalap New Drug Application For The Treatment Of Dry Eye Disease
17/06/2025 12:43
June 17 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS RESUBMITS REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF DRY EYE DISEASE ALDEYRA THERAPEUTICS INC - NO SAFETY CONCERNS IDENTIFIED IN CLINICAL TRIAL Source text: ID:nBw3Xb0fa Further company coverage: ALDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug